Skip to main content
SpringerLink
Log in

Immuntherapie des HL

Pembrolizumab bei rezidiviertem oder refraktärem Hodgkin-Lymphom

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Younes A et al. Lancet Oncol. 2016;17(9):1283-94

  2. Armand P et al. J Clin Oncol. 2018;36(14):1428-39

  3. Armand P et al. J Clin Oncol. 2016;34(31):3733-9

  4. Chen R et al. . J Clin Oncol. 2017;35(19):2132

  5. Chen R et al. Blood. 2019;134(14):1144-53

Download references

Author information

Authors and Affiliations

  1. Hämato-onkologische Gemeinschafts-, Winthierstr. 7, 80639, München, Germany

    Erhard Hiller

Authors
  1. Erhard Hiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiller, E. Pembrolizumab bei rezidiviertem oder refraktärem Hodgkin-Lymphom. Info Onkol. 22, 44–45 (2019). https://doi.org/10.1007/s15004-019-7226-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-7226-1

Search

Navigation